132 related articles for article (PubMed ID: 36994942)
1. Intentional overdose of glargine insulin: Determination of the parent compound in postmortem blood by LC-HRMS.
Arbouche N; Walch A; Raul JS; Kintz P
J Forensic Sci; 2023 May; 68(3):1077-1083. PubMed ID: 36994942
[TBL] [Abstract][Full Text] [Related]
2. Identification, measurement, and evaluation of blood concentrations of insulin glargine and insulin lispro by UPLC-MS-MS in a dead body suspected of insulin overdose.
Nagasawa S; Yamaguchi R; Chiba F; Torimitsu S; Iwase H
J Forensic Sci; 2023 Mar; 68(2):704-710. PubMed ID: 36762764
[TBL] [Abstract][Full Text] [Related]
3. Insulin glargine metabolite 21(A) -Gly-human insulin (M1) is the principal component circulating in the plasma of young children with type 1 diabetes: results from the PRESCHOOL study.
Danne T; Becker RH; Ping L; Philotheou A
Pediatr Diabetes; 2015 Jun; 16(4):299-304. PubMed ID: 25041275
[TBL] [Abstract][Full Text] [Related]
4. Plasma exposure to insulin glargine and its metabolites M1 and M2 after subcutaneous injection of therapeutic and supratherapeutic doses of glargine in subjects with type 1 diabetes.
Bolli GB; Hahn AD; Schmidt R; Eisenblaetter T; Dahmen R; Heise T; Becker RH
Diabetes Care; 2012 Dec; 35(12):2626-30. PubMed ID: 23093664
[TBL] [Abstract][Full Text] [Related]
5. Equipotency of insulin glargine 300 and 100 U/mL with intravenous dosing but differential bioavailability with subcutaneous dosing in dogs.
Werner U; Tennagels N; Fanelli CG; Bolli GB
Diabetes Obes Metab; 2021 Jan; 23(1):166-174. PubMed ID: 33001554
[TBL] [Abstract][Full Text] [Related]
6. Glargine metabolism over 24 h following its subcutaneous injection in patients with type 2 diabetes mellitus: a dose-response study.
Lucidi P; Porcellati F; Candeloro P; Cioli P; Andreoli AM; Marzotti S; Schmidt R; Bolli GB; Fanelli CG
Nutr Metab Cardiovasc Dis; 2014 Jul; 24(7):709-16. PubMed ID: 24702815
[TBL] [Abstract][Full Text] [Related]
7. Metabolism of insulin glargine after repeated daily subcutaneous injections in subjects with type 2 diabetes.
Lucidi P; Porcellati F; Rossetti P; Candeloro P; Andreoli AM; Cioli P; Hahn A; Schmidt R; Bolli GB; Fanelli CG
Diabetes Care; 2012 Dec; 35(12):2647-9. PubMed ID: 23086139
[TBL] [Abstract][Full Text] [Related]
8. Insulin glargine and its two active metabolites: A sensitive (16pM) and robust simultaneous hybrid assay coupling immunoaffinity purification with LC-MS/MS to support biosimilar clinical studies.
Xu Y; Sun L; Anderson M; Bélanger P; Trinh V; Lavallée P; Kantesaria B; Marcoux MJ; Breidinger S; Bateman KP; Goykhman D; Woolf EJ
J Chromatogr B Analyt Technol Biomed Life Sci; 2017 Sep; 1063():50-59. PubMed ID: 28846865
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro.
Lepore M; Pampanelli S; Fanelli C; Porcellati F; Bartocci L; Di Vincenzo A; Cordoni C; Costa E; Brunetti P; Bolli GB
Diabetes; 2000 Dec; 49(12):2142-8. PubMed ID: 11118018
[TBL] [Abstract][Full Text] [Related]
10. Intentional overdose with insulin glargine.
Ashawesh K; Padinjakara RN; Murthy NP; Nizar H; Anwar A
Am J Health Syst Pharm; 2009 Mar; 66(6):534. PubMed ID: 19265181
[No Abstract] [Full Text] [Related]
11. Biotransformation of insulin glargine after subcutaneous injection in healthy subjects.
Kuerzel GU; Shukla U; Scholtz HE; Pretorius SG; Wessels DH; Venter C; Potgieter MA; Lang AM; Koose T; Bernhardt E
Curr Med Res Opin; 2003; 19(1):34-40. PubMed ID: 12661778
[TBL] [Abstract][Full Text] [Related]
12. Detection of insulins in postmortem tissues: an optimized workflow based on immunopurification and LC-MS/HRMS detection.
Bottinelli C; Bévalot F; Cartiser N; Fanton L; Guitton J
Int J Legal Med; 2021 Sep; 135(5):1813-1822. PubMed ID: 33932171
[TBL] [Abstract][Full Text] [Related]
13. Detection of intact insulin analogues in post-mortem vitreous humour-Application to forensic toxicology casework.
Beckett N; Tidy R; Douglas B; Priddis C
Drug Test Anal; 2021 Mar; 13(3):604-613. PubMed ID: 33197145
[TBL] [Abstract][Full Text] [Related]
14. Glargine blood biotransformation: in vitro appraisal with human insulin immunoassay.
Agin A; Jeandidier N; Gasser F; Grucker D; Sapin R
Diabetes Metab; 2007 Jun; 33(3):205-12. PubMed ID: 17360218
[TBL] [Abstract][Full Text] [Related]
15. Octreotide for the treatment of hypoglycemia after insulin glargine overdose.
Groth CM; Banzon ER
J Emerg Med; 2013 Aug; 45(2):194-8. PubMed ID: 23669130
[TBL] [Abstract][Full Text] [Related]
16. Investigational new insulin glargine 300 U/ml has the same metabolism as insulin glargine 100 U/ml.
Steinstraesser A; Schmidt R; Bergmann K; Dahmen R; Becker RH
Diabetes Obes Metab; 2014 Sep; 16(9):873-6. PubMed ID: 24571126
[TBL] [Abstract][Full Text] [Related]
17. Simultaneous analysis of antihyperglycemic small molecule drugs and peptide drugs by means of dual liquid chromatography high-resolution mass spectrometry.
Vollmer AC; Wagmann L; Weber AA; Meyer MR
Clin Chem Lab Med; 2023 Jun; 61(7):1300-1308. PubMed ID: 37011023
[TBL] [Abstract][Full Text] [Related]
18. (Ultra-)long-acting insulin analogues versus NPH insulin (human isophane insulin) for adults with type 2 diabetes mellitus.
Semlitsch T; Engler J; Siebenhofer A; Jeitler K; Berghold A; Horvath K
Cochrane Database Syst Rev; 2020 Nov; 11(11):CD005613. PubMed ID: 33166419
[TBL] [Abstract][Full Text] [Related]
19. Intentional overdose with insulin glargine and insulin aspart.
Tofade TS; Liles EA
Pharmacotherapy; 2004 Oct; 24(10):1412-8. PubMed ID: 15628838
[TBL] [Abstract][Full Text] [Related]
20. Intravenous overdose of insulin glargine without prolonged hypoglycemic effects.
Thornton S; Gutovitz S
J Emerg Med; 2012 Sep; 43(3):435-7. PubMed ID: 22056549
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
